Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO Sells $480,750.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CFO John Todd Koning sold 37,500 shares of Alphatec stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the sale, the chief financial officer now owns 393,356 shares in the company, valued at approximately $5,042,823.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The shares were sold at an average price of $13.30, for a total value of $1,617,293.30.

Alphatec Stock Performance

NASDAQ:ATEC traded up $0.20 during mid-day trading on Friday, reaching $12.44. The company's stock had a trading volume of 1,256,848 shares, compared to its average volume of 1,614,289. Alphatec Holdings, Inc. has a 12-month low of $8.66 and a 12-month high of $19.14. The firm's fifty day moving average price is $13.69 and its two-hundred day moving average price is $13.46. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54. The stock has a market cap of $1.72 billion, a P/E ratio of -8.03 and a beta of 1.55.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09). The business had revenue of $138.00 million during the quarter, compared to analyst estimates of $131.90 million. During the same period last year, the business posted ($0.33) earnings per share. The business's revenue was up 30.3% compared to the same quarter last year. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Needham & Company LLC raised their price objective on Alphatec from $22.00 to $23.00 and gave the company a "buy" rating in a research report on Thursday, March 28th. Wells Fargo & Company initiated coverage on Alphatec in a research report on Friday, February 9th. They issued an "overweight" rating and a $26.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, March 4th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $25.00 price target on shares of Alphatec in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.63.

Institutional Investors Weigh In On Alphatec

Large investors have recently made changes to their positions in the company. BluePath Capital Management LLC bought a new stake in shares of Alphatec during the 3rd quarter valued at about $29,000. RiverPark Advisors LLC bought a new position in shares of Alphatec during the 3rd quarter valued at approximately $53,000. Provence Wealth Management Group bought a new position in shares of Alphatec during the 3rd quarter valued at approximately $56,000. Van ECK Associates Corp bought a new position in shares of Alphatec during the 3rd quarter valued at approximately $113,000. Finally, Tidemark LLC bought a new position in shares of Alphatec during the 4th quarter valued at approximately $137,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.